Definitive Treatment in Transition: De-Escalation, Biomarkers and Immunotherapy in Head and Neck Radiation Oncology Webinar
Immunotherapy has transformed the care of patients with recurrent/metastatic head and neck cancer but integration into definitive management has been more challenging.
Category
  • Head and Neck
  • Immunotherapy
Format
  • Upcoming Webinar
  • Webinars
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Evolving Multidisciplinary Management of Patients with Esophageal and Gastroesophageal Junction Cancer
The treatment landscape of esophageal and gastroesophageal junction cancer is evolving quickly with changes in the role of surgical management, emerging clinical data on the use of chemoradiation vs.
Category
  • Gastrointestinal
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Integrating Radiation Therapy with Novel Immunotherapies in the Management of Brain Metastases and Leptomeningeal Disease
With improved systemic therapy, the management of brain metastasis has become increasingly important. A number of immunotherapies and targeted agents have shown blood brain barrier penetration with a potential role in the upfront management of brain metastases and leptomeningeal disease.
Category
  • Central Nervous System
  • Immunotherapy
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
ASTRO/SNO Joint Activity: Current Multidisciplinary Management of Molecularly Defined IDH Mutant Grade 2 - 3 Glioma - Who, What, When, Why and How?
The management of patients with grade 2 – 3 glioma has recently become even more complicated due to incorporation of molecular findings for pathologic diagnosis, changing criteria for who is considered high risk, and variability in the use and choice of chemotherapy with radiotherapy.
Category
  • Central Nervous System
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Designing, Implementing and Interpreting Patient Reported Outcomes in Clinical Investigation
Patient reported outcomes (PROs) are a key component of evaluating cancer therapy. For clinical trialists, the proper design, implementation and evaluation of patient reported outcomes is critical for designing studies that will impact and inform daily practice.
Category
  • Professional Development
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00

Pages